September 2019

iMed.ULisboa Study: Anti-tumor Nanovaccines may hold the key for improving cancer immunotherapies

Investigators at the Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, University of Lisbon and the Tel Aviv University developed anti-tumor vaccines that may hold the key to improve the clinical outcomes of cancer therapies and be extremely relevant to design new cancer treatment strategies in the near future.

In a study just published in Nature Nanotechnology, led by Helena F. Florindo, group leader of BioNanoSciences – Drug Delivery and Immunotherapy at iMed.ULisboa and Ronit Satchi-Fainaro, professor from the Sackler Faculty of Medicine, Tel Aviv University, describe that the combination of their novel biodegradable anti-tumor vaccines with therapies available in the clinic, leads to remarkable tumor inhibition and prolonged survival in preclinical models of this disease.

This research was performed by João Conniot, investigator from the BioNanoSciences – Drug Delivery and Immunotherapy group at iMed.ULisboa and Anna Scomparin, investigator from the Tel Aviv University and describes the design and development of biodegradable nanoparticles, optimised for the delivery of combinations of multiple bioactive molecules with complementary mechanisms of action, such as tumor markers and immune adjuvants, to antigen-presenting cells of the immune system.